Paediatric indication for Xolair

The licence for Xolair (omalizumab), which is indicated for add-on therapy in severe persistent allergic IgE-mediated asthma, has been extended to include children as young as six years.

View Xolair drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

NSAIDs safe in COVID-19, study confirms

NSAIDs safe in COVID-19, study confirms

Concerns were raised early in the COVID-19 pandemic...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...